888 casino real money
PHILADELPHIA , Dec. 10, 2024 /PRNewswire/ -- The Dr. Zachary Solomon Scholarship for Medical Students is now accepting applications for its prestigious 2025 award. Designed to inspire and support the next generation of medical innovators, this scholarship reflects Dr. Zachary Solomon's unwavering commitment to advancing healthcare through education, research, and innovation. Dr. Zachary Solomon , a distinguished cardiothoracic surgeon renowned for his expertise in advanced cardiovascular surgery, has established this scholarship to nurture promising undergraduate students who demonstrate a clear dedication to the field of medicine. With a one-time award of $1,000 , the scholarship aims to catalyze the journey of aspiring medical professionals toward reshaping the future of patient care. A Vision Rooted in Excellence Dr. Zachary Solomon's illustrious medical career is marked by both clinical and academic achievements. After earning his Doctor of Medicine degree from George Washington University School of Medicine , Dr. Solomon pursued a rigorous general surgery residency at Memorial University Medical Center in Savannah, Georgia . Scholarship Details The Dr. Zachary Solomon Scholarship for Medical Students invites applications from undergraduate students enrolled in accredited programs and committed to pursuing careers in medicine. Applicants are required to demonstrate a genuine interest in advancing healthcare, whether through clinical practice, medical technology, or research. Interested candidates are encouraged to visit the scholarship's official website at drzacharysolomonscholarship.com to learn more about eligibility criteria and submission requirements. A Legacy of Healthcare Innovation Dr. Zachary Solomon's remarkable career has been defined by a relentless pursuit of excellence in cardiovascular and thoracic surgery, as well as his contributions to medical technology and research. This scholarship not only reflects Dr. Zachary Solomon's personal dedication to fostering innovation but also serves as a testament to his belief in the transformative power of education. His leadership inspires students to bridge the gap between medical advancements and patient care. Advancing the Future of Medicine Through the Dr. Zachary Solomon Scholarship for Medical Students , aspiring healthcare leaders have an opportunity to showcase their ideas, passion, and potential to shape the future of medicine. By encouraging students to think critically about medical advancements and their own roles in the evolving landscape of healthcare, this scholarship reinforces Dr. Zachary Solomon's lifelong commitment to innovation and education. For additional information, application guidelines, and resources, please visit drzacharysolomonscholarship.com . SOURCE Dr. Zachary Solomon ScholarshipThe Commission of Inquiry on Enforced Disappearance has found that the mobile surveillance system was used in pinpointing the location of the victims of the enforced disappearance prior to picking them up secretly. "Interviews with the victims and the members of the Armed Forces confirm that mobile technology was integral to the surveillance process. In interviews, RAB and military officers indicated that 'silent pick-ups'—unobtrusive abductions—were virtually impossible without mobile surveillance to pinpoint the victim's location with precision," said the Commission report, reports BSS. The five-member commission, led by retired justice Mainul Islam Chowdhury, recently presented the report, titled "Unfolding the Truth," to Chief Adviser Professor Muhammad Yunus at the state guest house Jamuna. Prior to the establishment of the National Telecommunication Monitoring Centre (NTMC) as an independent agency, the report said that the mobile surveillance was conducted through its predecessor, the National Monitoring Centre (NMC), which was housed within the DGFI (Directorate General of Forces Intelligence) Headquarters. The DGFI provided dedicated surveillance systems, which were also used by other forces, such as RAB and DB, implicating the DGFI in abetting the commission of enforced disappearances by forces other than its own, it said, adding that the NMC hosted dedicated consoles manned by personnel from various agencies, working in rotating shifts. A former DG of DGFI also confirmed to the Commission that his organization provided logistics support related to surveillance to various law enforcement teams whilst NMC was housed at the DGFI Headquarters. This operational structure again highlights significant coordination among security forces and since the establishment of the NTMC, surveillance activities have transitioned to this independent agency, it said. However, preliminary reports suggest that some surveillance capabilities still reside within individual forces. The extent of these capabilities remains an active line of inquiry, particularly because there appears to be no judicial oversight on the surveillance process, the Commission report said. "Despite the lack of judicial oversight, several victims reported signs of surveillance prior to their abductions," it said. For example, the report said that one victim revealed that his captors referenced a private phone conversation about his wife's dental treatment, suggesting that mobile surveillance had been conducted beforehand. Other victims described receiving suspicious phone calls shortly before their abductions, during which no one spoke at the other end of the line, it also said. "These calls were presumably used to pinpoint the victim’s location," it added. In another instance, the report said that eyewitnesses recounted how the security forces entered a room, instructed the occupants to place their phones in a line, and, when a call came to one of the phones, detained the individual who claimed it. "That person was never seen again," it said.
DOJ takes aim at ChromeParliament Winter Session To Begin Tomorrow, Waqf To Banking Laws Bill In Focus
None
Ambient.ai Unveils New Vision for Autonomous Physical Security with “Ambient Intelligence” Advanced AI Models6 Things You Need To Look Out For When Buying Used Computer Parts
Implements INDATA SaaS on a Front-to-Back Office Basis delivered via iPM Private Cloud GREENWICH, Conn. , Dec. 12, 2024 /PRNewswire/ -- INDATA , a leading industry provider of cloud-native, SaaS-based solutions for buyside firms, today announced that Paradigm Capital Management (PCM) is live with INDATA's Software-as-a-Service for Front, Middle and Back Office . With a three-decade history of small-cap investing, Paradigm Capital Management, based in Albany, NY employs a disciplined, bottom-up approach with an emphasis on fundamental analysis and extensive management contact. Paradigm manages $1.8 billion in AUM and offers a range of products including institutional separately managed accounts, proprietary mutual funds, and private wealth via hedge funds and LP's. Paradigm is using the INDATA system for a range of functions including trade order management (OMS), Portfolio Accounting , Performance and Reporting, including managed services for streamlined reconciliation. "We are very pleased to have Paradigm Capital Management as a client. We look forward to partnering with Paradigm on their ongoing needs," commented David Csiki , President of INDATA. About INDATA ® INDATA is a leading specialized provider of SaaS (Software-as-a-Service), technology and managed outsourcing services for buyside firms, including trade order management (OMS), portfolio management, compliance, portfolio accounting and front-to-back office. INDATA iPM Portfolio Architect AITM is the industry's first portfolio construction, modeling, rebalancing and reporting tool based on AI, and Machine Learning. INDATA's iPM – Intelligent Portfolio Management® technology platform allows end users to efficiently collaborate in real-time across the enterprise and contains the best of class functionality demanded by sophisticated institutional investors, wealth managers, and hedge funds. The company's mission is to provide clients with cutting edge technology products and services to increase trading and operational efficiency while reducing risk and administrative overhead. INDATA provides software and services to a variety of buyside clients including asset managers, registered investment advisors, banks and wealth management firms, pension funds and hedge funds. Assets under management range from under $1 billion to more than $100 billion across a variety of asset classes globally. For more information, visit www.indataipm.com Media Contact: David Csiki , dave@indataipm.com View original content: https://www.prnewswire.com/news-releases/paradigm-capital-management-live-with-indata-302330839.html SOURCE INDATALONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference in San Francisco in 2020, the forum has become a significant platform for advancing cell and gene therapy (CGT). This year's move to Europe underscores GenScript's commitment to driving the global CGT innovation and fostering international collaboration. "Putting patients first" is the underlying principle driving progress in the pharmaceutical industry and the inspiration behind this year's forum. "All our efforts in creating this platform for open dialogue and international collaboration in the CGT industry ultimately aim to address patient needs," said Jesse Chen, VP of Government Affairs and Corporate Communications at GenScript, in a pre-event interview. The forum brought together global thought leaders from academia, industry, and investment sectors in CGT to explore the theme "Unlock the Full Potential of Cell and Gene Therapies." Discussions focused on the latest breakthroughs, technological innovations, and future trends, offering multi-dimensional perspectives on advancing the CGT industry to benefit more patients. The forum was moderated by Dr. Shawn Wu, President of European Division at GenScript. Sherry Shao, Rotating CEO of GenScript, delivered the opening remarks, emphasizing: "Every step forward in CGT, every innovation, is ultimately about serving patients better." She reaffirmed GenScript's commitment to driving innovation in CGT and collaborating with global partners to bring life-changing therapies to more patients worldwide. The forum featured two keynote sessions with distinguished speakers: Dr. Miguel Forte, President of the International Society for Cell & Gene Therapy (ISCT), ARM Board Member, and CEO of Kiji Therapeutics, and Dr. James Wilson, a pioneer in gene therapy and President & CEO of Gemma Biotherapeutics (GEMMABio); Founder and Advisor of Scout Bio, Passage Bio, iECURE; Executive Chair at Franklin Biolabs. Their thought-provoking presentations not only deepened attendees' understanding of the field but also offered valuable insights into the future of cell and gene therapy (CGT). Dr. Forte's delivered a keynote titled "Status and Expectations for Cell and Gene Therapy in 2024 and Beyond," focused on the transformative potential of cell therapy. He delved into gene editing, in vivo therapies, and the challenges and opportunities associated with regulatory approval. He emphasized the importance of understanding the long-term nature of cell therapy development and the significance of global collaboration. Dr. Wilson's keynote, "The Case for Rare Diseases in Genetic Medicine Development," He emphasized the importance of gene therapy for rare diseases and elaborated on the commercialization challenges of gene therapy products and discussed issues encountered in clinical development, such as technological shortcomings, the complexity of clinical trials, and production challenges. Dr. Wilson also emphasized the importance of patient advocacy and social media in promoting drug accessibility and raising public awareness. Additionally, he highlighted the need to focus on reimbursement mechanisms and achieve a balance between innovation and the resource utilization of health authorities. In addition to the compelling keynote speeches, the forum featured a range of dynamic interactive sessions, including three roundtable discussions and a fireside chat. These sessions attracted significant attention, offering lively debates and actionable insights that resonated with the audience. The success of CAR-T therapies in hematologic malignancies has revealed the vast potential of cell therapies. Now, the focus is on extending these breakthroughs to broader patient populations, including those with solid tumors and autoimmune diseases, which have become a shared goal across the industry. During the "Technology Innovation and Breakthroughs in Cell Therapy" roundtable, Mr. Stephen Hansen, Director of Biopharma Intelligence at BioCentury, moderated a vibrant discussion featuring leaders such as Dr. Ying Huang, CEO of Legend Biotech, Dr. Reagan Jarvis, CEO and Co-founder of Anocca, Dr. Pascal Touchon, Chairman of the Board at Atara Biotherapeutics, Mr. Jason Foster, CEO and Executive Director of Ori Biotech, and Dr. Biao Zheng, CEO of BRL Medicine. They approached the topic from the patient's perspective, highlighting the exceptional efficacy of CAR-T therapy. The experts also shared promising clinical data on the use of CAR-T drugs for autoimmune diseases and expressed high hopes for their future development. They emphasized that developing more patient-friendly, user-friendly CAR-T therapies is critical for increasing patient acceptance. Additionally, expanding production capacity, improving product accessibility, and ensuring product safety are urgent priorities. Collaboration with medical centers is key to developing commercially viable products. As innovative therapies continue to be researched, the potential applications of CAR-T therapy will be further unlocked, offering patients more treatment options. Driven by technological breakthroughs, significant progress has been made in gene therapy and mRNA vaccine fields, with applications expanding rapidly. However, the production of these therapies is complex, particularly when it comes to the choice, production, and optimization of delivery vectors, which have a profound impact on their development. In the roundtable discussion on "Progress in Gene Therapy and mRNA Vaccine," hosted by Ms. Kristina Cornish, Partner at Pinsent Masons, London & European and UK Patent Attorney, leading researchers including Mr. Deividas Pazeraitis, Senior Scientist at AstraZeneca, Dr. Karim Benabdellah, Principal Investigator at GENYO, Dr. Maelle Quere, Scientist at Sanofi, Dr. Vincenzo Di Cerbo, Lead Technical Scientist at Cell and Gene Therapy Catapult, and Dr. Lumeng Ye, Director of Novel therapeutic materials at GenScript; all agreed that long-term delivery efficiency and technological bottlenecks remain key challenges in translating innovations into clinical applications. The discussion focused on the technological trends and innovative developments in the clinical applications of gene editing, the topics cover the selection of viral vectors (VP), non-viral vectors (NVP), lipid nanoparticles (LNP), and virus-like particles (VLP) in different application areas, the innovative developments in gene therapy and mRNA vaccines, as well as an analysis of the advantages and disadvantages of mRNA vaccines compared to traditional vaccines, along with development trends and application prospects. They also provided a comprehensive review of the progress from technological innovation to clinical application in this field and unanimously agreed that long-term delivery technology and in vitro cell line technology remain key challenges. The development process for CGT is highly complex and personalized, and these characteristics are seen as major challenges to the continuous supply of these therapies. In the subsequent roundtable discussion on "CMC Challenges with Developing & Manufacturing Cell and Gene Therapies," led by Dr. Qingyu Cao, Senior Director & head of European Business Development at ProBio, and panelists are Dr. Jim Faulkner, CEO of JDB BioConsulting, Mr. Arindam Mitra, CMC Director at Leucid Bio, Dr. Dima Al-hadithi, Director at Minaret Consulting Limited, and Ms. Ming Ewe, CEO of Smarter Biotech Solutions, engaged in lively discussions on key issues such as production process standardization, quality control, and viral vector production. The discussion presented practical strategies and solutions, providing important references for the widespread application of CGT. The experts emphasized the need for early planning of CMC and regulatory strategies in the context of accelerated approval processes, ensuring that product development and quality control can proceed in parallel. They also highlighted the importance of selecting the right CDMO partners to support full collaboration. Furthermore, they suggested that efforts should begin early in the R&D phase, with active communication with regulatory agencies to enhance the understanding of new technologies and methods, and a clear supply chain map should be created to ensure stable supply. Regarding future trends, the experts believe that AI technology will play a key role in optimizing gene therapy design, improving production efficiency, and advancing automation processes. They are confident that, with ongoing technological advancements and increasing market competition, the price of CGT therapies will gradually decrease, making them a widely accessible treatment option. R&D and manufacturing in the cell and gene therapy field require substantial financial investment, with long return cycles, making funding pressure a key constraint on industry growth. In the closing fireside chat, "Navigating the Future of CGT: Insights from Investors," was moderated by Dr. Kelly Shi, Senior VP & Research Analys at Jefferies LLC, Dr. Josh Resnick, Senior Managing Director at RA Capital Management, and Mr. Ping Shek, Managing Director at Stifel's Investment Banking Division, discussed the investment landscape for CGT. The speakers shared their investment insights in the CGT field, reviewing the evolution of the sector from its early boom to the current adjustment phase. When discussing investment strategies, the participants highlighted key considerations such as addressing patient needs, reducing uncertainty in research and development as well as manufacturing, and increasing commercialization success rates. They also emphasized the need for continued innovation in reducing manufacturing costs. Regarding the investment trend in CGT, despite market fluctuations, signs of recovery began to emerge in 2023, indicating a positive outlook for future capital inflows. Currently, investment behavior is becoming more cautious, and the market is steadily moving toward normalization. Furthermore, the evolving regulatory environment and changes in reimbursement policies have had a profound impact on investment decisions. Addressing infrastructure development and therapy accessibility is viewed as a core driver for the sustained growth of the industry. The GenScript Biotech Global Forum concluded successfully with engaging discussions from experts and scholars. This event brought together global leaders from the biopharmaceutical industry, who shared valuable experiences and unique insights, injecting fresh momentum into the continued development and innovation of the global cell and gene therapy sector. Moving forward, GenScript Biotech remains committed to building more open and inclusive collaboration platforms to drive innovation and progress in the field of cell and gene therapy. As an annual event, the GenScript Global Forum will continue to uphold its core focus of "patient-centered" goals, advancing scientific innovation and market applications in cell and gene therapies, bringing greater hope for a healthier global future. About GenScript Biotech Corporation GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacture. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and Cell Therapy Business Unit. GenScript accelerates scientific discovery and therapeutic breakthrough with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 5060 employees. As of June 30, 2024, over 100,000 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world. For more information, please visit GenScript Biotech's official website https://www.genscript.com View original content: https://www.prnewswire.com/news-releases/the-genscript-biotech-global-forum-makes-a-strong-debut-in-europe-highlighting-breakthroughs-in-cell-and-gene-therapy-development-302313220.html SOURCE GenScript Biotech Corporation
Hyderabad: It was a moment of pride for the transgender community of Telangana as 39 transgenders recruited as traffic police assistants in the police department recently, performed the “traffic drill” before Hyderabad police commissioner CV Anand at the Integrated Command Control Centre (ICCC) of Hyderabad police department on Sunday, December 22. The newly recruited traffic police assistants from the transgender community performing the traffic drill at the Integrated Command Control Centre (ICCC) in Hyderabad on Sunday. pic.twitter.com/1EX2dypE6v These new traffic police assistants who have received training for 15 days will begin their duties starting Monday, December 23. The transgender traffic police assistants have been posted with the same status as Home Guards. A post shared by The Siasat Daily (@siasatdaily) Addressing them, CV Anand said that their performance in their new duties was crucial as the state government was contemplating inducting the transgenders into various other government departments based on this pilot project. He also said that the entire country was looking at the initiative in Telangana which would set a new precedent for social acceptance of the community which has suffered social stigma for ages. Terming the government’s initiative as “innovative and revolutionary,” CV Anand said that it was a great opportunity for the transgenders to integrate with society and that stationing them at traffic signals was one of the most suitable jobs for them, as they were all well acquainted with such locations.
The oceans, encompassing over 70% of the Earth's surface, are vital lifelines for biodiversity and economic prosperity. They are reservoirs of opportunities for sustainable development, encapsulated within Sustainable Development Goal (SDG) 14: 'Life Below Water'. This goal emphasises conserving marine resources while leveraging their potential for economic growth. Central to this ambition is the concept of the Blue Economy, introduced by Gunter Pauli in his 2010 book The Blue Economy: 10 Years, 100 Innovations, 100 Million Jobs. Pauli envisioned oceans as "development spaces", where conservation aligns with the sustainable use of resources. The World Bank defines the Blue Economy as "the sustainable use of ocean resources for economic growth, improved livelihoods, and jobs while preserving the health of ocean ecosystems". Similarly, the European Commission describes it as encompassing "all economic activities related to oceans, seas, and coasts, including fisheries, aquaculture, maritime transport, and renewable energy". This vision encompasses fisheries, aquaculture, maritime shipping, renewable ocean energy, coastal tourism and marine biotechnology. According to a World Bank report, globally, the Blue Economy generates around $2.3 trillion annually, contributing to food security, poverty eradication and climate change mitigation. According to FAO, marine ecosystems are integral to global well-being. Oceans provide sustenance to over three billion people, with fish accounting for 16% of the global animal protein supply. Livelihoods for 660820 million people rely on fisheries and aquaculture, with women playing a critical role, particularly in fish processing, where they hold up to 90% of jobs. Furthermore, the World Bank report says that oceans absorb 25% of anthropogenic CO2 emissions, with "blue carbon" sinks such as mangroves and seagrasses proving five times more effective than tropical forests at sequestering carbon. For Pakistan, the Blue Economy is an untapped frontier. With a 1,046 km coastline and a vast Exclusive Economic Zone (EEZ) by the Arabian Sea, Pakistan's maritime potential remains largely underutilised. The maritime sector contributes only 2.4% of GDP, as per the Pakistan Economic Survey 20232024, with fisheries exports at just $450 million annually. In contrast, regional peers earn billions from marine resources. Estimates suggest Pakistan could generate over $100 billion annually from its Blue Economy with the right strategies (World Bank Group report). However, Pakistan's marine economy faces several challenges. Overfishing, habitat degradation, pollution and unregulated coastal development hinder sustainability. Illegal, unreported and unregulated fishing exacerbates the problem, with global losses estimated at $1022 billion annually as per the FAO Report. Climate change, including rising sea levels, coastal erosion and ocean acidification, further threatens livelihoods and ecosystems. Fragmented governance structures and inadequate infrastructure add to these issues. Despite these hurdles, opportunities abound for Pakistan to leverage its marine potential. Examples from Morocco, Indonesia and Oman highlight the impact of governance reforms and targeted investments. Morocco, backed by the World Bank, developed its aquaculture sector, creating rural jobs, especially for women. Indonesia employs mobile technologies to monitor fisheries, improving biodiversity conservation. Oman's fisheries management is a benchmark for balancing ecology and economic growth. To realise its Blue Economy potential, Pakistan must implement a comprehensive approach. Reforms like Integrated Coastal Zone Management (ICZM) and marine spatial planning can align conservation with economic activities. Clear policies and tenure rights can empower communities to adopt sustainable practices. Digital tools for maritime mapping and data-driven monitoring can improve decision-making and resource management. Public-private partnerships in fisheries, renewable energy and marine biotechnology can foster innovation and economic diversification while attracting needed capital. Pakistan's scenic beaches, such as Gwadar and Kund Malir, have immense potential for eco-tourism. Investments in infrastructure, conservation and community engagement can attract global visitors and preserve natural habitats. Small-scale fishers and women in supply chains must be prioritised through policies and capacity-building programmes to ensure equitable access to resources and inclusive growth. Regional cooperation to address shared issues like illegal fishing and marine pollution can also drive collective progress. Empowering coastal communities is central to the Blue Economy. Small-scale fishers, often the most impacted by resource degradation, must have a role in governance and decision-making. This not only ensures equity but also enhances compliance with sustainable practices. Globally, fisheries rebuilding efforts are more successful when local stakeholders are involved. Pakistan's reliance on maritime transportation for 95% of its imports and exports underscores the strategic importance of coastal infrastructure (Pakistan Economic Survey 202324). Modernising ports and improving logistics can make Pakistan a regional maritime hub, boosting trade efficiency. Renewable ocean energy projects, like tidal and wave energy, can help address Pakistan's energy crisis while cutting carbon emissions. Protecting mangroves and coastal ecosystems is crucial for carbon sequestration and climate resilience. Declining mangrove cover threatens biodiversity and causes economic losses exceeding $4 billion annually, as seen in Belize. Restoring these habitats can deliver ecological and economic benefits. The oceans are Pakistan's gateway to sustainable development. Localising SDG 14 and embracing the Blue Economy, Pakistan can transform its marine resources into a foundation for economic growth and environmental stewardship. Visionary leadership, innovative governance and a commitment to sustainability are essential to secure Pakistan's maritime future, set a global example and ensure its oceans remain a source of life and livelihood for generations to come. COMMENTS Comments are moderated and generally will be posted if they are on-topic and not abusive. For more information, please see our
Falcons Announce Three Moves
Remarkable new battery splits water to create hydrogen fuel
What Amazing Feat Did Tesla’s Robot Just Master?BWISE Solutions Exclusive Webinar: How BWISE Positively Transforms Businesses for the Holidays
No. 5 UCLA stuns top-ranked South Carolina in 15-point blowout to snap Gamecocks' 43-game win streakRico Carty, who won the 1970 NL batting title with the Atlanta Braves, has died
The all-new platform to be powered by technology from Sologenic and leverage Texture Capital's deep expertise as a licensed broker-dealer for digital asset securities SoloTex will layer technology and expertise in asset tokenization from CoreNest Capital's partner companies Sologenic and Coreum underneath Texture Capital's position as a FINRA Member and SEC-registered broker-dealer for digital asset securities. With Texture's Alternative Trading System (ATS) infrastructure and Transfer Agent capabilities, it aims to provide a complete, end-to-end solution for tokenizing and trading securities, backed by the company's expertise in navigating the evolving U.S. regulatory landscape. ” Sologenic 's track record in product development and tokenization as well as CoreNest's commitment to this space will help drive our mission to bridge the gap between traditional and nontraditional digital assets and transform capital markets through tokenization,” said Richard Johnson, CEO of Texture Capital. "Together we are excited to tokenize real-world assets leveraging blockchain and deliver the benefits of DeFi to traditional markets.” Through CoreNest Capital's investment and technological contributions, Texture Capital is well-positioned to continue transforming capital markets through tokenization. Sologenic's comprehensive ecosystem of blockchain-based applications are designed for the highest standards of user experience and security in handling these assets. "Innovation is the constant in an ever-fluctuating market,” said Bob Ras , GP & Co-Founder of CoreNest Capital. "This partnership with Texture Capital is not constrained to launching a platform; it's about laying the groundwork for a new era of asset management applications and investment strategies driven by innovation, transparency and security.” SoloTex has created a waitlist for early access ahead of regulatory submission and official platform launch. Visit http://solotex.com to join the waitlist. About CoreNest Capital CoreNest Capital is a venture capital firm that focuses on tech investments in areas like AI, robotics, fintech, and medtech. CoreNest Capital is a catalyst for nurturing and funding startups in cutting-edge sectors. About Texture Capital Holdings Texture Capital Holdings is the parent of Texture Capital Inc, a FINRA member and broker-dealer specializing in digital securities, and Texture Transfer Services LLC, an SEC-registered Transfer Agent. We empower clients to compliantly issue tokens representing equity, debt, revenue share, royalties, or other investment contracts. Leveraging blockchain technology and smart contracts, we aim to transform the traditional capital markets' structure, offering tools for issuance, tokenization, and secondary market trading via our Alternative Trading System. About Sologenic Founded in 2020, Sologenic is a leader in tokenization, offering on-demand solutions for institutional and retail markets. Its advanced trading infrastructure supports blockchain-native assets, stablecoins, and soon, tokenized securities, bridging traditional finance with blockchain innovation. Contact: Pedro Crespo CoreNest Capital [email protected] A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e190056d-36d0-43bb-b0b1-fd866a715251FG eyes 25,000 jobs from Lagos textile, garment economic zone